mg twice 30 d intervals had CHF (NYHA (29%) had no premature in daily) . tachycardia study patents while taking discontinuation w/ PSVT placebo. during PSVT, (n=14, Group flecainide PAF, 1) Number w/ no treatment tachycardia periods (5 pts PAF or increased w/ in Group 1 and atrial parosysmal progressively 6 pts in Group flutter atrial flutter larger 2). (n=28, Group flecainide 2) doses; w/ the 150 mg twice daily dose, 12 (86%) of 14 pts had no tachycardia (p<0.01 for overall differences among all treatments). Pritchett Oral 23 Propafenone Placebo PSVT Angina during Compared w/ Cardiac AEs N/A N/A Propafenone EL (n=23) (n=23) (n=14) tachycardia, placebo, occurred only in efficacious in 1991 one to pulmonary edema, propafenone pts w/ PAF treating PSVT (28) prevent PAF neurologic caused an (9/11): 2 w/ and PAF. (n=9) sxs. increase in prolonged PAF w/ WPW time to first episode of AF, Major PSVT syndrome, on AADs recurrence of 1 w/ atrial flutter limitation in arrhythmia w/ a mean not knowing (p=0.004) ventricular how many pts rate of 263 bpm had AVNRT. PSVT: recorded using . p=0.03 the telephone monitor. PAF: d, p=0.06 . phase, w/ each period lasting up to 60 d. Efficacy 87 Diltiazem Placebo Induction of PSVT w/ Pts w/ severe Conversion to N/A Most N/A IV diltiazem in AH and PES, required congestive heart sinus rhythm frequent doses of 0.15, 1992 safety of AVNRT to have a rate of 120 failure, sinus node occurred in 4 adverse 0.25 and 0.45
in patents w/ PSVT, PAF, atrial flutter mg twice daily) PSVT (n=14, Group 1) PAF or parosysmal atrial flutter (n=28, Group 2) 30 d intervals had CHF (NYHA . (29%) had no tachycardia while taking placebo. Number w/ no tachycardia increased w/ progressively larger flecainide doses; w/ the 150 mg twice daily dose, 12 (86%) of 14 pts had no tachycardia (p<0.01 for overall differences among all treatments). premature study discontinuation during flecainide treatment periods (5 pts in Group 1 and 6 pts in Group 2). Pritchett EL 1991 (28) Oral to prevent PSVT phase, w/ each period lasting up to 60 d. 23 Propafenone (n=23) Placebo (n=23) PSVT (n=14) PAF (n=9) Angina during tachycardia, pulmonary edema, neurologic sxs. PAF w/ WPW syndrome, on AADs Compared w/ placebo, propafenone caused an increase in time to first recurrence of arrhythmia (p=0.004) PSVT: p=0.03 PAF: p=0.06 . Cardiac AEs occurred only in pts w/ PAF (9/11): 2 w/ prolonged episode of AF, 1 w/ atrial flutter w/ a mean ventricular rate of 263 bpm recorded using the telephone monitor. N/A N/A Propafenone efficacious in treating PSVT and PAF. Major limitation in not knowing how many pts had AVNRT. . AH 1992 Efficacy and safety of 87 AVNRT Diltiazem Placebo Induction of PSVT w/ PES, required to have a rate of 120 Pts w/ severe congestive heart failure, sinus node Conversion to sinus rhythm occurred in 4 N/A Most frequent adverse N/A IV diltiazem in doses of 0.15, 0.25 and 0.45 d, one
2015_SVT_Evidence_Tables_Data_Supplement.docx